Betaxolol Tablets Rx
Generic Name and Formulations:
Betaxolol HCl 10mg+, 20mg; tabs; +scored.
Various generic manufacturers
Indications for Betaxolol Tablets:
Initially 10mg daily alone or added to diuretic therapy; may increase to 20mg daily after 7–14 days; usual max 20mg daily. Elderly or severe renal dysfunction: initially 5mg daily.
Sinus bradycardia. 2nd- or 3rd-degree AV block. Cardiogenic shock. Overt heart failure.
CHF. Bronchospastic disease, COPD. Diabetes. Hyperthyroidism. Renal or hepatic dysfunction. Avoid abrupt cessation. Surgery. SLE. Elderly. Pregnancy (Cat.C). Nursing mothers.
Increased cardiac effects of calcium channel blockers, digitalis. Bradycardia with catecholamine-depleting drugs. May block epinephrine. May interfere with glaucoma screening tests.
Bradycardia, headache, GI upset, dizziness, arthralgia, fatigue, dyspnea, chest pain, pharyngitis, impotence, heart failure, bronchospasm.
Formerly known under the brand name Kerlone.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|